Altorki, N K <br/><br/>
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jul 2003 
 - 2645-50 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2003.07.127  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Celecoxib<br/>Chemotherapy, Adjuvant<br/>Cyclooxygenase Inhibitors--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Synergism<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Pneumonectomy<br/>Preoperative Care--methods<br/>Pyrazoles<br/>Sulfonamides--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome